MaxCyte, Inc. reported earnings guidance for the year ended December 31, 2016. The company reported that revenues for the full year 2016 are expected to be in line with market expectations, at approximately $12.2 million, an increase of more than 30% over 2015 revenues of $9.3 million. In addition, the company reports that CARMA expenditures and Loss Before Tax are likely to be an improvement on market expectations.